The prostate cancer is a worldwide disease with high mortality rate and traditional methods for diagnosis and monitoring are performed through invasive techniques. Currently, the advance of research in medical and biomedical engineering allowed the use of molecular tools combined with nanotechnology to develop portable biosensors specific for major biomarkers to diagnostic, monitoring and treatment of several diseases. More specifically, the cellular responses to biological, chemical or physical stimuli can be evaluated in microfluidic devices using electrochemical techniques. The objective of this project is the development of integrated biosensors to study different cell biomarkers released by prostate cancer cells, as: free prostatic specific antigen (fPSA), vascular endothelial growth factor (VEGF), mucin (MUC1), hexokinase type 2 (hK2), prostatic specific membrane antigen (PSMA), androgen receptor (AR) and prostatic acid phosphatase (PAP) and moreover, evaluate metabolic activity combined with drug delivery systems in a device where the cellular microenvironment can be precisely defined offering new insights into the molecular metabolism events and for clinical analysis patients with prostate cancer.
News published in Agência FAPESP Newsletter about the scholarship: